Bradley J . Monk, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Affiliate Professor

General

• Levin Gabriel, Monk Bradley, Gilbert Lucy, Coleman Robert, Ribeiro Reitan, Gender and geographic disparity in industry payments to gynecologic oncologists in the United States 2026

Publications

• Gynecologic oncology
  Zimmerman Jenna, Krivak Thomas C, Crafton Sarah M, Miller Eirwen M, Monk Bradley J, Dadgar Neda, Immune checkpoint inhibition in ovarian cancer: Reassessing its potential
  211, p. 138 2026
• Gynecologic oncology
  Shahin Mark S, McCormick Colleen C, Abadie-Lacourtoisie Sophie, Willmott Lyndsay J, Monk Bradley J, Lorusso Domenica, Backes Floor J, Barretina-Ginesta Maria-Pilar, O'Malley David M, Forget Frédéric, Pothuri Bhavana, Hietanen Sakari, , Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
  211, p. 79 2026
• ESMO open
  Sukhin V.S., Podzielinski I., Herzog T.J., Mathews C., Gill S.E., Ronzino G., Gilbert L., Koliadi A., Kommoss S., Edelson M., Monk B.J., , 71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
  11, p. 108097 2026
• ESMO open
  Slomovitz B.M., Monk B.J., Tewari K.S., Cloven N., Farolfi A., Ferrero A., Cibula D., Dubot C., Barraclough L., Madrid L. Fariñas, , 48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer
  11, p. 108073 2026
• ESMO open
  Prendergast E., Kim J-W., Salutari V., Ciuleanu T-E., Barlin J.N., Del Prado M.P. Martinez, Pothuri B., Fujiwara K., Van Gorp T., Weber K., Craib M., Monk B.J., Kuru O., Zagouri F., Shirinkin V., Westin S., Bobinski M., Kristeleit R., 112RO Subsequent anti-cancer therapy (SACT) of patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in ATHENA-MONO/GOG-3020/ENGOT-ov45
  11, p. 108159 2026
• Gynecologic oncology
  Bogani Giorgio, Taylor Hugh S., Moore Kathleen N., Ray-Coquard Isabelle, Ceccaroni Marcello, Coleman Robert L., Fotopoulou Christina, Mabrouk Mohamed, Roman Horace, Ferrari Filippo A., Monk Bradley J., , Corrigendum to ‘Endometriosis and ovarian cancer risk’ [Gynecologic Oncology 209C (2026) 88–98]
  210, p. 113 2026
• Journal of clinical oncology
  Slomovitz Brian M., Cloven Noelle, Monk Bradley J., Tewari Krishnansu Sujata, Dubot Coraline, Farolfi Alberto, Ferrero Annamaria, Cibula David, Fariñas-Madrid Lorena, Barraclough Lisa, , TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1-positive cervical cancer
  44:16_suppl, p. TPS5628 - TPS5628 2026
• Journal of clinical oncology
  Barlin Joyce N., Hand Lauren, Black Destin, Cottrill Hope M., Eshed Helen Dinkelspiel, O'Malley David M., Monk Bradley J., Hopp Elizabeth, Lim Peter C., Thomes Pepin Jessica, Cloven Noelle, , Overall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumab
  44:16_suppl, p. 5511 - 5511 2026
• Journal of clinical oncology
  Monk Bradley J., O'Malley David M., Romero Ignacio, Martinez Mena Corina, Willmott Lyndsay, Auranen Annika, Slomovitz Brian M., Bergamini Alice, Prendergast Emily N., de La Motte Rouge Thibault, , Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial
  44:16_suppl, p. 5565 - 5565 2026
• Journal of clinical oncology
  Gaillard Stephanie, Cantillo Evelyn, Denys Hannelore, Cibula David, Clamp Andrew R., Crafton Sarah, Hasegawa Kosei, Finkelstein Karen, Gil-Martin Marta, Monk Bradley J., Hanker Lars Christian, , Puxitatug samrotecan (AZD8205) vs chemotherapy in patients with B7-H4-selected advanced/metastatic endometrial cancer: The phase 3 randomized Bluestar-Endometrial01 (BE01)/GOG-3110/ENGOT-EN28 trial
  44:16_suppl, p. TPS5647 - TPS5647 2026
• Journal of clinical oncology
  Monk Bradley J., Corr Bradley, Puvvada Soham D., Mei Lin, Opneja Aman, Patel Vishal, Altomare Ivy, Ferhat Abdennour, Stirnadel-Farrant Heide A., Beckermann Kathryn E., Zhang Tian, Schmidt James, Sarlo Kristen, A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors: DESTINY-PanTumor04
  44:16_suppl, p. TPS11202 - TPS11202 2026
• Gynecologic oncology
  Bogani Giorgio, Monk Bradley J., Coleman Robert L., Fotopoulou Christina, Taylor Hugh S., Roman Horace, Mabrouk Mohamed, Ferrari Filippo A., Ray-Coquard Isabelle, Ceccaroni Marcello, Moore Kathleen N., , Endometriosis and ovarian cancer risk
  209, p. 88 - 98 2026
• Gynecologic oncology
  Slomovitz Sadie, Podder Vivek, Eubanks Rhea, Randall Leslie, Campbell-Simms Katie, Slomovitz Brian, O'Malley David, Copeland Larry, Coleman Robert, Herzog Thomas, Pothuri Bhavana, Eskander Ramez, Monk Bradley, Moore Kathleen, Reliability of feasibility surveys for predicting patient accrual in phase III gynecologic trials
  208, p. S142 - S142 2026
• Gynecologic oncology
  Monk Bradley, Korach Jacob, Hasegawa Kosei, Kose Fatih, Ibañez Carolina, Zsiros Emese, Sebastianelli Alexandra, Mądry Radosław, Diaz Roberto Ivan Romero, Hudson Emma, , Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study
  208, p. S31 - S31 2026
• Gynecologic oncology
  Backes Floor, Forget Frédéric, O'Malley David, Barretina-Ginesta Maria-Pilar, Monk Bradley, Willmott Lyndsay, Raaschou-Jensen Nicoline, Pisano Carmela, Follana Philippe, O'Cearbhaill Roisin, , Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Results from the homologous recombination-deficient (HRd) and -p
  208, p. S25 - S26 2026
• Gynecologic oncology
  Van Gorp Toon, Boere Ingrid, Oaknin Ana, denys hannelore, Ghamande Sharad, Monk Bradley, Tromp Jacqueline, Vergote Ignace, Randall Leslie, Cibula David, Lorusso Domenica, , Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: First disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study
  208, p. S37 - S38 2026
• Gynecologic oncology
  Grisham Rachel, O'Malley David, Monk Bradley, Van Nieuwenhuysen Els, Santin Alessandro, D'Hondt Véronique, Aghajanian Carol, Thaker Premal, Clamp Andrew, Moore Kathleen, Perez-Fidalgo Alejandro, , Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201
  208, p. S30 - S31 2026
• Gynecologic oncology
  Slomovitz Brian, Monk Bradley, Eskander Ramez, Starks David, Barlin Joyce, Mallen Adrianne, Wysham Weiya, Hester Danubia, Lee Christine, Anderson Charles, Alvarez Edwin, Jackson Amanda, Rubinstein Maria, Maddocks Oliver, Choksi Mamta, Chirnomas Debbie, Crafton Sarah, DiBenedetto Samantha, Niazi Tina, Sapanisertib and serabelisib (PIKTOR) with paclitaxel, and an insulin-suppressing diet (ISD) substudy, in patients with advanced/recurrent endometrial cancer (EC): GOG-3111
  208, p. S105 - S105 2026
• Gynecologic oncology
  Levin Gabriel, Coleman Robert, Monk Bradley, Ribeiro Reitan, Gilbert Lucy, From PARPis to ADCs: Changing patterns of industry payments to gynecologic oncologists
  208, p. S191 - S191 2026
• Gynecologic oncology
  Kim Jae-Weon, Mallen Adrianne, Yadav Bhagyashree, Pai Sachin, Slomovitz Brian, Monk Bradley, Lorusso Domenica, Park Jeong-Yeol, Colombo Nicoletta, Felberbaum Ricardo, Thaker Premal, Muller Carolyn, Gladieff Laurence, Olawaiye Alexander, Van Gorp Toon, Bertrán Ana Santaballa, Bodnar Lubomir, Madrid Lorena Fariñas, Pashova Hristina, BELLA: A phase 2 study of relacorilant plus nab-paclitaxel +/− bevacizumab in patients with gynecologic cancers
  208, p. S107 - S107 2026
• Gynecologic oncology
  Monk Bradley, Vulsteke Christof, Sánchez Luis Manso, Braicu Elena Ioana, Madry Radoslaw, Beijers Antoinetta J.M., Farolfi Alberto, Hasegawa Kosei, Alexandre Jerome, Wang Jian-Liu, , GOG-3119/ENGOT-en29/TroFuse-033: A phase 3, randomized study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
  208, p. S103 - S104 2026
• The Lancet (British edition)
  Lorusso Domenica, Monk Bradley J, Gladieff Laurence, O'Malley David M, Mileshkin Linda, Quesada Stanislas, Hopp Elizabeth, Gilbert Lucy, Kim Jae-Weon, Garbaos Gabriel, Fagotti Anna, , Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
  407:10538, p. 1513 - 1524 2026
• The Lancet (British edition)
  Colombo Nicoletta, Bidzinski Mariusz, Gallardo Carlos, Matanes Emad, Hasegawa Kosei, Zsiros Emese, Parma Gabriella, Rulli Eliana, Sebastianelli Alexandra, Kose Fatih, Monk Bradley J, , Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
  407:10538, p. 1525 - 1537 2026
• Targeted therapies in oncology
  Monk Bradley, KEYNOTE-B96 Brings Immunotherapy-Based Option to Platinum-Resistant Ovarian Cancer 2026
• Gynecologic oncology
  Levin Gabriel, Monk Bradley J, Gilbert Lucy, Coleman Robert L, Meyer Raanan, Ribeiro Reitan, Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends
  207S, p. 60 2026
• Gynecologic oncology
  Van Nieuwenhuysen Els, Vergote Ignace, Randall Leslie M, Tromp Jacqueline, Pisano Carmela, Lorusso Domenica, O'Cearbhaill Roisin E, Boere Ingrid, Sanchez Luis Manso, Banerjee Susana, Monk Bradley J, , Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
  207S, p. 3 - 13 2026
• Banerjee Susana, Aghajanian Carol, D'Hondt Veronique, Monk Bradley, Oaknin ANA, Van Nieuwenhuysen Els, Clamp Andrew, The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201 2026
• International journal of gynecological cancer
  Denschlag Dominik, Cloven Noelle, Pennington Kathryn, Monk Bradley J., Mccourt Carolyn, Powell Matthew A., Roed Henrik, Gilbert Lucy, Zub Oleksandr, Fleming Evelyn, Angioli Roberto, , Post-hoc survival outcomes based on initial and subsequent treatment in patients with mmrp/MSS primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
  36:2, p. 104434 2026
• International journal of gynecological cancer
  Konstantinopoulos Panagiotis, Song Mihae, Eskander Ramez N., Matei Daniela, Guy Michael, Winer Ira, Bradley William H., Brubaker Lindsay W., Mcnamara Donna, Turner Rachael, Monk Bradley J., , CLINICAL ACTIVITY OF ACR-368 IN PATIENTS WITH ENDOMETRIAL CARCINOMA PROSPECTIVLY SELECTED BY ONCOSIGNATURE – A PHASE 2 STUDY - ACR-368-201/GOG3082 (NCT05548296)
  36:2, p. 104573 2026
• International journal of gynecological cancer
  González-Martín Antonio, O'Malley David M., Galaz Cristina Churruca, Vulsteke Christof, Chase Dana M., Koliadi Anthoula, Braly Patricia, Lorusso Domenica, Chan John K., D'Hondt Véronique, Willmott Lyndsay J., Monk Bradley J., , Predictors of long-term progression-free survival in patients treated with niraparib first-line maintenance therapy in the phase 3 randomised placebo-controlled PRIMA/ENGOT-OV16/GOG-3012 trial
  36:2, p. 103081 2026
• International journal of gynecological cancer
  Zagouri Flora, Prado Purificación Martinez- Del, Diaz John Paul, Zeng Xing, Lu Chien-Hsing, Jewell Andrea, Salutari Vanda, Van Le Linda, Kuru Oguzhan, Collins Dearbhaile C., Bradford Leslie S., Chudecka-Glaz Anita, Bradley William H., Fujiwara Keiichi, Holloway Robert, Borrow Jen, Ong Valerie, Kristeleit Rebecca S., Monk Bradley J., Rucaparib maintenance in ATHENA-MONO (GOG-3020/ENGOT-ov45) in patients with newly diagnosed advanced ovarian cancer: exploratory post-progression evaluations for patients with HRD-negative and HRD-unknown tumours
  36:2, p. 103090 2026
• International journal of gynecological cancer
  Eminowicz Gemma, Tlustý Vojtech, Concin Nicole, Mcsorley Lynda M., Zagouri Flora, Fujiwara Keiichi, Matanes Emad, Petrella Maria Cristina, Nilsen Elisabeth Berge, Wang Jian Liu, Monk Bradley J., , GOG-3119/ENGOT-en29/TROFUSE-033: A phase 3, randomised study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
  36:2, p. 104392 2026
• JCO precision oncology
  Coleman Robert L, Wallraven Gladice, Willoughby David, Nagel Casey, Wei Qi, Horvath Staci, Stanbery Laura, Rocconi Rodney, Monk Bradley J, Walter Adam, Nemunaitis John, Tang Min, Rao Donald, Bognar Ernest, Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer
  10:10, p. e2500462 2026
• Graybill Whitney S, Pardo Búrdalo Beatriz, O’Malley David M, Copeland Larry J, Sabbatini Roberto, Herzog Thomas J, Follana Philippe, Auranen Annika, Monk Bradley J, Vergote Ignace, , Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study 2025
• Future oncology (London, England)
  Banerjee Susana N, Van Nieuwenhuysen Els, Aghajanian Carol, Rodrigues Manuel, Chon Hye Sook, Ring Kari, Monk Bradley J, Clamp Andrew, D'Hondt Véronique, Prendergast Emily, Oaknin Ana, Colombo Nicoletta, Newman Gregg, Salinas Erin, Youssoufian Hagop, Santin Alessandro D, O'Malley David M, Gourley Charlie, Thaker Premal H, Van Gorp Toon, Grisham Rachel N, Lustgarten Stephanie, Holloway Robert W, Gennigens Christine, Moore Kathleen N, The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201, p. 1 2025
• Moore Kathleen, Grisham Rachel, Fabbro MICHEL, OMalley David, Monk Bradley, Van Nieuwenhuysen Els, GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer 2025
• International journal of gynecological cancer
  Eskander Ramez N., Slomovitz Brian, Makker Vicky, Fujiwara Keiichi, Moore Kathleen N., Monk Bradley, Gonzalez-Martin Antonio, Oza Amit, Oaknin Ana, Leary Alexandra, Sehouli Jalid, Rider Alex, Brown Tom, Ali Talal, Smith Alan, Gourley Charlie, REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED PLATINUM-RESISTANT AND PLATINUM-SENSITIVE OVARIAN CANCER WITHIN THE UNITED STATES: AN ANALYSIS OF SECONDARY DATA
  35:11, p. 102488 2025
• International journal of gynecological cancer
  Hasegawa Kosei, Yañez Eduardo, Gumus Mahmut, Arkhipov Alexander, Hurtado De Mendoza Mivael Olivera, Samouëlian Vanessa, Castonguay Vincent, Tekin Cumhur, Toker Sarper, Monk Bradley, Li Kan, Colombo Nicoletta, Tewari Krishnansu S., Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Shapira-Frommer Ronnie, Salman Pamela, PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826
  35:11, p. 102156 2025
• International journal of gynecological cancer
  Lee Elizabeth, Yeku Oladapo, Call Justin, Winer Ira, Richardson Debra, Seamon Leigh, Hamilton Erika, Monk Bradley, Cloven Noelle, Zhang Jian, Kavalerchik Edward, PART C OF RAINFOL™-01: A PHASE 1/2 STUDY OF SINGLE-AGENT RINATABART SESUTECAN IN PATIENTS WITH ADVANCED AND/OR METASTATIC PLATINUM-RESISTANT OVARIAN CANCER
  35:11, p. 102616 2025
• International journal of gynecological cancer
  Richardson Debra, Weiner Ira, Willmott Lyndsay J., Call Justin, Pepin Jessica Thomes, Jewell Andrea, Mathews Cara, Seamon Leigh, Buscema Joseph, Monk Bradley, Guancial Elizabeth, Orr Douglas, Melnyk Anton, Gillespie Michael, Kilavuz Nurgul, Ong Teng Jin, Kavalerchik Edward, Cloven Noelle, Konecny Gottfried, Lee Elizabeth, RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
  35:11, p. 102612 2025
• International journal of gynecological cancer
  Salani Ritu, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Lee Jung-Yun, Van Gorp Toon, Boere Ingrid, Duska Linda, Marth Christian, Mądry Radosław, Zagouri Flora, Monk Bradley, Li Xin Tong, Bogusz Agata M., Toker Sarper, Lindemann Kristina, Cáceres M. Valeria, Harter Philipp, Zhongqiu Lin, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Valabrega Giorgio, Canova Stefania, TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
  35:11, p. 102609 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, Sill Michael, Lankes Heather, Newton Meredith, Leitao Mario, Ramondetta Lois, Clair Kiran, Guntupalli Saketh, Iii Charles Leath, Richardson Debra, Disilvestro Paul, Cantuaria Guillerme, Billingsley Caroline, Mcdonald Megan, Monk Bradley, Liu Yingmiao, Starr Mark, Birrer Michael, Brady Chris, Lea Jayanthi, Ueland Frederick, Chambers Laura, Tewari Krishnansu S., Nixon Andrew, PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240
  35:11, p. 102158 2025
• International journal of gynecological cancer
  Nicum Shibani, Marth Christian, Lu Chien-Hsing, Monk Bradley, Crafton Sarah, Zagouri Flora, Segev Yakir, Collins Dearbhaile C., Kümmel Jan, Petrella Maria Cristina, Lassus Heini J., Fujiwara Keiichi, Wang Jian Liu, Jaishuen Atthapon, Cáceres M. Valeria, Freitas-Junior Ruffo, Kruger Stephan, Black Destin, Slomovitz Brian M., Orlowski Robert, Yao Lili, GOG-3119/ENGOT-EN29/TROFUSE-033: A PHASE 3, RANDOMIZED STUDY OF SACITUZUMAB TIRUMOTECAN PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE THERAPY FOR MISMATCH REPAIR-PROFICIENT ENDOMETRIAL CANCER
  35:11, p. 102611 2025
• International journal of gynecological cancer
  Vergote Ignace, Cibula David, Perez Fidalgo Jose Alejandro, Valabrega Giorgio, Monk Bradley, Herzog Thomas, Colombo Nicoletta, Pothuri Bhavana, Sehouli Jalid, Korach Jakob, Richardson Debra, Barlin Joyce, Papadimitriou Christos, Van Gorp Toon, Mccarthy Michael, Antill Yoland, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert, ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
  35:11, p. 102472 2025
• International journal of gynecological cancer
  Lorusso Domenica, Monk Bradley, Martin Lainie, Schenker Michael, Maximiano Constanza, Barlin Joyce, Kim Yong Man, Bese Tugan, Rose Peter G., Chang Chih-Long, Pospiskova Marketa, Salinas Erin A., Malander Susanne, Santin Alessandro D., Collins Dearbhaile C., Willmott Lyndsay, Craib Marcia, Chui Joshua, Fujiwara Keiichi, Kristeleit Rebecca, SAFETY OF RUCAPARIB MONOTHERAPY IN ADVANCED HIGH-GRADE OVARIAN CANCER CLINICAL TRIALS
  35:11, p. 102262 2025
• Gynecologic oncology
  Chase Dana M, Cho Chi Heum, Kim Jae-Weon, No Jae Hong, Smick Alexandra H, Holman Laura, Stuckey Ashley, Fabian Denise, Wenzel Lari, Gil Karen, Ryu Sang Young, Rodgers William, Huang Helen Q, Deng Wei, Koh Wui-Jin, Leath Charles A, Small, Jr William, Albuquerque Kevin, Mayadev Jyoti, Monk Bradley, Kim Beob-Jong, Kim Dae-Yeon, Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)
  202, p. 102 - 109 2025
• Journal of clinical oncology
  Monk Bradley J, Coleman Robert L, O'Malley David M, Moore Kathleen N, González-Martín Antonio, Herzog Thomas J, Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer, p. JCO2501721 2025
• Molecular cancer therapeutics
  Leary Alexandra, Willmott Lyndsay, Monk Bradley J., Frenel Jean-Sébastien, Starks David C., Okera Meena, Secord Angeles Alvarez, O’Malley David M., Martin Lainie, Ouali Kaissa, Oehler Martin K., Goh Jeffrey C., Slomovitz Brian M., Lim Peter C., Shannon Catherine M., Neff Robert, Backes Floor J., Rajendran Divya, Chung Heekyung, Kim Doris, Li Hailun, Jandial Danielle, Simpkins Fiona, Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
  24:10_Supplement, p. B013 - B013 2025
• Annals of oncology
  Kristeleit R S, Yeku O, Pisano C, Buscema J, Demirkiran F, Ueland F, Chudecka-Głaz A, Prendergast E, Kim Y B, Fuentes Pradera J, Oaknin A, Chou H-H, Provencher D, Zagouri F, Martin L P, Eskander R N, Beiner M, Anderson C, Drochytek V, O'Malley D M, Littell R D, Gao B, Valabrega G, Shih D, Agarwal R, Maloney L, Despain D, Connor C, Craib M, Fujiwara K, Monk B J, Dean A, Lisyanskaya A, Ghamande S, Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study 2025
• Journal of clinical oncology
  Banerjee Susana N, D'Hondt Véronique, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley J, Clamp Andrew, Prendergast Emily, Holloway Robert W, Oaknin Ana, Ring Kari, Colombo Nicoletta, Rodrigues Manuel, Chon Hye Sook, Gennigens Christine, Gourley Charlie, Santin Alessandro D, Thaker Premal H, Newman Gregg, Salinas Erin, Youssoufian Hagop, Van Gorp Toon, Moore Kathleen N, Lustgarten Stephanie, O'Malley David M, Grisham Rachel N, Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2502377 2025
• Obstetrical & gynecological survey
  Olawaiye Alexander B., Vergote Ignace, Kesner-Hays Amanda, Pashova Hristina I., Pai Sachin G., Tudor Iulia Cristina, Jubb Adrian M., Lorusso Domenica, Salutari Vanda, O'Malley David M., Kim Jae-Weon, Garbaos Gabriel, Artioli Grazia, Caruso Giuseppe, Nicum Shibani, Bagameri Andrea, Bodnar Lubomir, Kim Byoung-Gie, Colombo Nicoletta, De La Creva Helena, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, do Carvalho Calabrich Aknar Freire, Cassani Chiara, You Benoit, Lee Yong Jae, Churruca Cristina, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Hopp Elizabeth, Oaknin Ana, Scaranti Mariana, Leiser Aliza L., McCollum Michael E., Diakos Connie, Clamp Andrew, Balazs Boglárka, Monk Bradley J., Scandurra Giuseppa, Kang Sokbom, Gladieff Laurence, Van Gorp Toon, Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
  80:10, p. 636 - 638 2025
• Annals of oncology
  Ryu S Y, Leath, 3rd C A, Gil K M, Small, Jr W, Rodgers W, Monk B J, Koh W-J, Heugel A, Fabian D, Chase D M, Miller K, No J H, Mannel R S, Cho C-H, Deng W, Albuquerque K, Mayadev J, Kim J-W, Kim B-J, Kim D-Y, Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008 2025
• Konstantinopoulos Panagiotis A, Kim Jae Weon, Freyer Gilles, Colombo Nicoletta, Lee Jung Yun, Gaba Lydia, Grisham Rachel N, Wu Xiaohua, Sehouli Jalid, Cruz Felipe, Friedlander Michael, Cibula David, Monk Bradley J, Nyvang Gitte Bettina, Lorusso Domenica, Van Nieuwenhuysen Els, Malik Rozita, Cortés-Salgado Alfonso, Glasspool Rosalind, Marth Christian, Leary Alexandra, Zamagni Claudio, Marmé Frederik, Sufliarsky Jozef, Su Fei, Zuradelli Monica, Wang Craig, Hinson Patsy, Paule Ines, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Primary Analysis of EPIK-O/ENGOT-ov61:Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation 2025
• Gynecologic oncology
  Levin Gabriel, Pothuri Bhavana, Monk Bradley, Coleman Robert, Herzog Thomas, Slomovitz Brian, Racial and ethnic enrollment disparities in clinical trials leading to drug approvals for gynecologic malignancies by the Food and Drug Administration
  200, p. 150 2025
• Gynecologic oncology
  Lee Elizabeth, Seamon Leigh, Call Justin, Winer Ira, Yeku Oladapo, Richardson Debra, Hamilton Erika, Cloven Noelle, Zhang Jian, Kavalerchik Edward, Monk Bradley, Part C of a phase I/II study evaluating single agent rinatabart sesutecan in patients with advanced and/or metastatic platinum-resistant ovarian cancer
  200, p. 112 - 113 2025
• Gynecologic oncology
  File Brittany, Kapp Daniel, Monk Bradley, Francoeur Alex, Tran Nathan, Richardson Michael, Herzog Thomas, Coleman Robert, Tewari Krishnansu, Chan John, Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years
  200, p. 114 - 115 2025
• Gynecologic oncology
  Salani Ritu, Kurtz J. Emmanuel, Lindemann Kristina, Zhongqiu L.I.N., Nishio Shin, Oaknin Ana, Valabrega Giorgio, Canova Stefania, Cáceres M. Valeria, Lee Jung-Yun, Harter Philipp, Gilbert Lucy, Sadozye Azmat, Van Gorp Toon, Boere Ingrid, Marth Christian, Duska Linda, Madry Radoslaw, Zagouri Flora, do Rêgo Barros Lilian Arruda, Monk Bradley, Li Xin Tong, Bogusz Agata, Toker Sarper, Mirza Mansoor, TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical c
  200, p. 121 - 122 2025
• Gynecologic oncology
  Richardson Michael, Kapp Daniel, Chan John, Herzog Thomas, Coleman Robert, Monk Bradley, Gynecologic cancers in tumor-agnostic trials: Keys to regulatory approval
  200, p. 74 2025
• Gynecologic oncology
  Bujnak Alyssa, Hamilton Alina, Hari Anjali, Hoadley Katherine, Lankes Heather, Tewari Krishnansu, Monk Bradley, Birrer Michael, Sill Michael, Szot Christopher, Wei Lei, Ramirez Nilsa, Huang Helen, Landrum Lisa, Liu Hongwei, Penson Richard, Ramondetta Lois, Michael Helen, Oaknin Ana, Reid Thomas, Leitao Mario, Copeland Larry, Jones Corbin, Reeves Catherine, Predictive biomarkers for chemotherapy plus bevacizumab in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 National Institutes of Health Cancer Moonshot
  200, p. 352 - 353 2025
• Gynecologic oncology
  Lee Jung-Yun, Oaknin Ana, Lee Yeh Chen, Lorusso Domenica, Kim Kidong, Gilbert Lucy, Gao Bo, Tan David, Monk Bradley, Oza Amit, Miller Rowan, O'Malley David, Pothuri Bhavana, Lu Lin, Berman Craig, Naumann Wendel, Borgman Anne, Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study
  200, p. 351 2025
• Annals of oncology
  Mercieca-Bebber R., Holschneider C., Buck M., Brooks S., Lea J., Stuckey A., Lad T.E., Spirtos N., Boyd L., Fyles A., Monk B., Barnes E., Stockler M., King M.T., Mileshkin L., Moore K., Diamante K., Lee Y.C., Narayan K., Khaw P., 1172P The relationship between patient-reported outcomes and clinician-rated toxicity in participants with locally advanced cervix cancer in the OUTBACK trial
  36, p. S772 - S773 2025
• Annals of oncology
  Lorusso D., Muller C.Y., Monk B.J., Park J-Y., Colombo N., Van Gorp T., Kim J-W., Gladieff L., Olawaiye A., Madrid L. Fariñas, Bertrán A. Santaballa, Felberbaum R., Bodnar L., Pai S., Thaker P.H., Pashova H.I., Yadav B.K., Mallen A., 1239eTiP BELLA: A phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer
  36, p. S748 - S748 2025
• Annals of oncology
  Monk B.J., Lorusso D., Van Nieuwenhuysen E., Tromp J., Zikan M., O'Cearbhaill R.E., Banerjee S., Collins D.C., Jackson A.L., Madsen K., Gennigens C., Salutari V., Ottevanger P.B., Ghamande S., Baurain J-F., Reyners A., Conte U., Windfeld K., Hansen H., Vergote I., 1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
  36, p. S769 - S770 2025
• Gynecologic oncology
  Chase Dana, Monk Bradley, Small William, Huang Helen, Deng Wei, Rodgers William, Mayadev Jyoti, Leath Charles, Kim Beob-Jong, Albuquerque Kevin, Kim Dae-Yeon, Cho Chi-Heum, Gil Karen, Ryu Sang Young, Stuckey Ashley, Kim Jae-Weon, No Jae Hong, Holman Laura, Fabian Denise, Smick Alexandra, Wenzel Lari, Patient-reported outcomes on a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate-risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy (NCT#01101451)
  200, p. 4 - 5 2025
• Gynecologic oncology
  Simpkins Fiona, Leary Alexandra, Willmott Lyndsay, Monk Bradley, Frenel Jean-Sebastien, Goh Jeffrey, Slomovitz Brian, Lim Peter, Shannon Catherine, Neff Robert, Kim Doris, Li Hailun, Jandial Danielle, Backes Floor, Starks David, Okera Meena, Secord Angeles Alvarez, O'Malley David, Martin Lainie, Ouali Kaissa, Oehler Martin, Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)
  200, p. 8 - 9 2025
• Gynecologic oncology
  Ryu Sang Young, Albuquerque Kevin, Deng Wei, Koh Wui-Jin, Mayadev Jyoti, Heugel Anne, Kim Beob-Jong, Miller Katherine, Kim Dae-Yeon, Cho Chi-Heum, Kim Jae-Weon, No Jae Hong, Mannel Robert, Fabian Denise, Small William, Rodgers William, Leath Charles, Monk Bradley, Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical carcinoma following radical hysterectomy and lymphadenectomy: Results of NRG oncology/GOG-263
  200, p. 4 2025
• Gynecologic oncology
  Grisham Rachel, Van Nieuwenhuysen Els, Aghajanian Carol, Ring Kari, Monk Bradley, Clamp Andrew, D’hondt Veronique, Prendergast Emily, Oaknin Ana, Derio Silvia, Holloway Robert, Rodrigues Manuel, Chon Hye Sook, Gourley Charlie, Santin Alessandro, Thaker Premal, Gennigens Christine, Newman Gregg, Salinas Erin, Youssoufian Hagop, Van Gorp Toon, Banerjee Susana, O'Malley David, Moore Kathleen, Lustgarten Stephanie, ENCORE: Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (ENGOT-OV60/GOG-3052/RAMP 201): Dose intensity and subgroup analysis
  200, p. 34 - 35 2025
• Cancer treatment and research communications
  Monk Bradley J., Gordan Lucio N., Patel Manish R., Toker Sarper, Subbiah Vivek, DEVELOPMENT OF ANTI-CANCER MEDICINES IN THE CURRENT ERA, p. 101002 - 101002 2025
• International journal of gynecological cancer
  Podder Vivek, Coleman Robert L., Eskander Ramez, Flint Michelle, Monk Bradley J., Slomovitz Brian M., Checkpoint Inhibitor Rechallenge in Advanced Endometrial Cancer: Revisiting the Immune Landscape Beyond First-Line Therapy, p. 102124 2025
• Journal of clinical oncology
  Konstantinopoulos Panagiotis A, Su Fei, Hinson Patsy, Zuradelli Monica, Wang Craig, Paule Ines, Kim Jae Weon, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Freyer Gilles, Lee Jung Yun, Wu Xiaohua, Gaba Lydia, Grisham Rachel N, Colombo Nicoletta, Monk Bradley J, Sehouli Jalid, Cruz Felipe, Cibula David, Van Nieuwenhuysen Els, Nyvang Gitte-Bettina, Friedlander Michael, Lorusso Domenica, Leary Alexandra, Malik Rozita, Glasspool Rosalind, Marth Christian, Sufliarsky Jozef, Cortés-Salgado Alfonso, Zamagni Claudio, Marmé Frederik, Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation, p. JCO2500225 2025
• Journal of clinical oncology
  Banerjee Susana N, Monk Bradley J, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Véronique, Prendergast Emily, Oaknin Ana, Ring Kari, Clamp Andrew, Colombo Nicoletta, Holloway Robert W, Rodrigues Manuel, Youssoufian Hagop, Chon Hye Sook, Gourley Charlie, Santin Alessandro D, Thaker Premal H, Gennigens Christine, Newman Gregg, Salinas Erin, Moore Kathleen N, Grisham Rachel N, Lustgarten Stephanie, O'Malley David M, Van Gorp Toon, , Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2500112 2025
• Gynecologic oncology
  Chan John K., McHale Michael T., Tewari Krishnansu, Monk Bradley J., Herzog Thomas J., Coleman Robert L., Richardson Michael T., Salani Ritu, Francoeur Alex A., Kapp Daniel S., Optimizing therapy for cervical cancers – Translating trial data into clinical decision-making
  199, p. 47 - 50 2025
• Annals of oncology
  Mayadev J, Rey F, Kahán Z, Galaz P, Meléndez Mier G, Wu X, Mandai M, Estevez-Diz M D P, Limaye S, Xin W, Shapira-Frommer R, Stewart R A, Dry H, Broggi M A S, Yuan D Y, Monk B J, Varga S, Ramírez Godinez F J, Leiva M, Cetina-Pérez L D C, Molina Alavez A, Alarcon-Rozas A E, Valdiviezo N, Acevedo C, Figueroa A, Santini A, Vera L, Vázquez Limón J C, Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses 2025
• The Lancet (British edition)
  Olawaiye Alexander B, Artioli Grazia, Gladieff Laurence, O'Malley David M, Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Caruso Giuseppe, Nicum Shibani, Bagaméri Andrea, Kesner-Hays Amanda, Bodnar Lubomir, Kang Sokbom, Vergote Ignace, Jubb Adrian M, Pashova Hristina I, Pai Sachin G, Tudor Iulia Cristina, Hopp Elizabeth, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Kim Byoung-Gie, Lorusso Domenica, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, Clamp Andrew, Colombo Nicoletta, McCollum Michael E, Diakos Connie, Scandurra Giuseppa, Leiser Aliza L, Balázs Boglárka, Monk Bradley J, De La Cueva Helena, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, de Carvalho Calabrich Aknar Freire, Churruca Cristina, Cassani Chiara, You Benoit, Van Gorp Toon, Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 2025
• International journal of gynecological cancer
  Lightfoot Michelle DS, Lutz Kathleen, Rubinstein Maria M., Monk Bradley J., Eskander Ramez N., Pothuri Bhavana, Herzog Thomas J., Moore Kathleen N., Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment, p. 101997 2025
• Journal of clinical oncology
  Bujnak Alyssa, Birrer Michael J., Hamilton Alina, Sill Michael, Monk Bradley J., Hari Anjali, Penson Richard T., Lankes Heather A., Hoadley Katherine A., Liu Hongwei, Szot Christopher, Ramondetta Lois M., Oaknin Ana, Leitao Mario Mendes, Copeland Larry J., Ramirez Nilsa C., Wei Lei, Tewari Krishnansu Sujata, miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot
  43:16_suppl, p. 5523 - 5523 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, Alvarez Ronald D., Small Michelle N., Randall Leslie M., Mannel Robert S., Mutch David, Coleman Robert L., Herzog Thomas J., Monk Bradley J., Moore Kathleen N., Copeland Larry J., Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc.’s Scholar Career Development Award and New Investigator Program, p. 101982 2025
• Journal of clinical oncology
  Shahin Mark S., Moore Richard G., Hietanen Sakari, O’Cearbhaill Roisin E., Mangili Giorgia, Berton Dominique, Rubio-Pérez Maria Jesús, Burger Robert Allen, Braicu Elena Ioana, Monk Bradley J., Shtessel Luda, Cloven Noelle, Aaquist Haslund Charlotte, Herzog Thomas J, Lim Jonathan, Gonzalez Martin Antonio, McCormick Colleen C., Barretina-Ginesta Maria-Pilar, O’Malley David M., Honhon Brigitte, Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC)
  43:16_suppl, p. 5551 - 5551 2025
• Journal of clinical oncology
  Mayadev Jyoti, Vázquez Limón Juan Carlos, RamIrez Godinez Francisco Javier, Leiva Manuel, Alarcon-Rozas Ashley Efrain, Cetina Lucely Del Carmen, Varga Szilvia, Molina Alavez Alejandro, Valdivieso Natalia, Wu Xiaohua, Limaye Sewanti Atul, Mandai Masaki, Shapira-Frommer Ronnie, Estevez-Diz Maria Del Pilar, Xin Wenjing, Broggi Maria, Stewart Ross, Monk Bradley J., Yuan Daniel Y., Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses
  43:16_suppl, p. 5502 - 5502 2025
• Journal of clinical oncology
  Salani Ritu, Lin Zhongqiu, Lindemann Kristina, Mirza Mansoor Raza, Nishio Shin, Cáceres Valeria, Oaknin Ana, Kurtz Jean Emmanuel, Valabrega Giorgio, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat, De Rêgo Barros Lilian Arruda, Boere Ingrid A., Li Xin Tong, Marth Christian, Duska Linda R., Monk Bradley J., Tekin Cumhur, , TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer
  43:16_suppl 2025
• Journal of clinical oncology
  Mercieca-Bebber Rebecca, Lee Yeh Chen, Barnes Elizabeth H., Moore Kathleen N., Fyles Anthony, Narayan Kailash, Khaw Pearly, Buck Martin, Brooks Susan, Lad Thomas E., Lea Jayanthi Sivasothy, Stuckey Ashley, Holschneider Christine, Spirtos Nicola M., Stockler Martin R., Boyd Leslie R., Small William, Monk Bradley J., Mileshkin Linda R., King Madeleine T., Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial
  43:16_suppl, p. 5503 - 5503 2025
• ESMO open
  Oaknin A., Littell R., Fujiwara K., Kristeleit R., Monk B.J., Prendergast E., Salutari V., Schenker M., Martinez-Garcia J., Yeku O., Ueland F., Lee J-Y., De Vivo R., Dean A., Diaz J., Bese T., Jewell A., Van Gorp T., Maloney L., 75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency
  10 2025
• ESMO open
  Okines A., Oh D-Y., Curigliano G., Mizuno N., Rorive A., Hamilton E.P., Soliman H., Takahashi S., Bekaii-Saab T., Monk B.J., Nakamura Y., Ramos J.D., Nguyen D., O'Malley D., Reck M., Yu E., Drees A., Tan Q., Stinchcombe T., Pohlmann P.R., 304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)
  10, p. 104876 2025
• International journal of gynecological cancer
  Podder Vivek, Cobb Lauren Patterson, Grisham Rachel N., Coleman Robert L., Slomovitz Brian M., Monk Bradley J., Herzog Thomas, Gershenson David M., Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment, p. 101938 2025
• Cancer treatment reviews
  Monk Bradley J., Sehouli Jalid, Lorusso Domenica, Fujiwara Keiichi, Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review, p. 102945 2025
• Gynecologic oncology
  Matulonis Ursula A., Mahner Sven, Berton Dominique, Berek Jonathan S., Redondo Andrés, Herrstedt Jørn, Oza Amit, Lindahl Gabriel, Haslund Charlotte A., Marmé Frederik, Tinker Anna V., Ledermann Jonathan A., Benigno Benedict, Mirza Mansoor R., Bains Manjinder, González-Martín Antonio, Bécourt Stéphanie, Colombo Nicoletta, Malinowska Izabela A., Liu Wenlei, Monk Bradley J., ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
  195, p. 192 2025
• Gynecologic oncology
  Leath, 3rd Charles A, Holman Laura L, Deng Wei, Mell Loren K, Richardson Debra L, Walker Joan L, Arend Rebecca C, Lea Jayanthi S, Amarnath Sudha R, Santos-Reyes Luis Javier, Chon Hye Sook, Mayadev Jyoti, Jegadeesh Naresh, DiSilvestro Paul, Chino Junzo P, Ghamande Sharad A, Gao Lei, Albuquerque Kevin, Quick Allison M, Donnelly Eric, Feddock Jonathan M, Lowenstein Jessica, Monk Bradley J, Aghajanian Carol, Kunos Charles M, MacKay Helen, Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
  195, p. 122 - 133 2025
• International journal of gynecological cancer
  Leitao Mario M., Randall Leslie M., Lim Peter C., Bixel Kristin L., Chase Dana Meredith, Quick Allison, McCormick Colleen, Black Destin, Eskander Ramez N., Gotlieb Walter H., LoCoco Salvatore, Martino Martin A., Walker Joan L., Copeland Larry J., Monk Bradley J., ROCC/GOG-3043: A randomized controlled trial of robotic versus open surgery for early-stage cervical cancer, p. 101760 2025
• International journal of gynecological cancer
  Salani Ritu, Lindemann Kristina, Lin Zhongqiu, Valabrega Giorgio, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Cáceres M. Valeria, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Boere Ingrid, Marth Christian, Monk Bradley J., Li Xin Tong, Tekin Cumhur, Mirza Mansoor Raza, Duska Linda, TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
  35:2, p. 100497 2025
• International journal of gynecological cancer
  Ghamande Sharad, Prendergast Emily, Miller Rowan E., Solovyeva Ekaterina, Del Mar Gordon Santiago Maria, Kim Yong-Man, Littell Ramey, Fujiwara Keiichi, Anttila Maarit, Connor Christy, Craib Marcia, Monk Bradley J., Kristeleit Rebecca S., Turna Hande, Ruiz Nuria, Bessette Paul, Van Le Linda, Westin Shannon N., Zvaríková Mária, Eskander Ramez N., ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100319 2025
• International journal of gynecological cancer
  Lokich Elizabeth, Jørgensen Trine Lembrecht, Black Destin, Cibula David, Gilbert Lucy, Savarese Antonella, Powell Matthew A., Herbertson Rebecca, Gill Sarah E., Monk Bradley J., Nevadunsky Nicole, Cloven Noelle, Podzielinski Iwona, Myers Tashanna, Dabrowski Christine, Ring Kari L., Stevens Shadi, Willmott Lyndsay, Mirza Mansoor Raza, Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
  35:2, p. 101722 2025
• Therapeutic advances in medical oncology
  Powell Matthew A, Novák Zoltán, Black Destin, Gilbert Lucy, Sharma Sudarshan, Stuckey Ashley, Boere Ingrid, Gold Michael A, Segev Yakir, Pothuri Bhavana, Monk Bradley J, Shahin Mark S, Grimshaw Matthew, Stevens Shadi, Lai Dominic W, McCourt Carolyn, Mirza Mansoor Raza, Buscema Joseph, Coleman Robert L, Gennigens Christine, Sebastianelli Alexandra, Gill Sarah E, Valabrega Giorgio, Landrum Lisa M, Gropp-Meier Martina, Slomovitz Brian M, Ring Kari L, Herzog Thomas J, Balas Morad Marco, Bjørge Line, Willmott Lyndsay, A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
  17, p. 17588359251342241 2025
• Journal of gynecologic oncology
  Kim Yong-Man, Tewari Krishnansu S., Hasegawa Kosei, Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Kim Se Ik, Lee Jeong-Won, Liou Wen-Shiung, Li Kan, Nishio Shin, Tekin Cumhur, Colombo Nicoletta, Monk Bradley J., Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
  36 2025
• International journal of gynecological cancer
  Barlin Joyce, Black Destin, Cottrill Hope, Hand Lauren, Eshed Helen, O’Malley David, Chuang Linus, Chisamore Michael, Durbin Joan, Zheng Pan, Lim Peter, Pepin Jessica Thomes, Hopp Elizabeth, Cloven Noelle, Monk Bradley, Liu Yang, Shpyro Svetlana, LB010/#1590  A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
  34, p. A6 - A8 2024
• International journal of gynecological cancer
  Lorusso Domenica, Van Gorp Toon, Zagouri Flora, Bodnar Lubomir, Collins Dearbhaile, Korach Jacob, Marth Christian, Kroep Judith, Zhu Jianqing, Hasegawa Kosei, Samouëlian Vanessa, Lee Jung-Yun, Casarotto Fernanda, Antill Yoland, Chase Dana, Shahin Mark, Orlowski Robert, Woodhouse Kristina, Cui Yi, Willmott Lyndsay, Monk Bradley, TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
  34, p. A348 - A348 2024
• International journal of gynecological cancer
  Vergote Ignace, Barlin Joyce, Papadimitriou Christos A, Colombo Nicoletta, Valabrega Giorgio, Monk Bradley J, Herzog Thomas, Perez Fidalgo Alejandro, Cibula David, Pothuri Bhavana, Sehouli Jalid, Korach Jacob, van Gorp Toon, Richardson Debra, McCarthy Michael, Antill Yoland, Mirza Mansoor Raza, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert L, ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: ratio
  34:8, p. 1283 2024
• Gynecologic oncology
  Valabrega Giorgio, Graybill Whitney S, Pothuri Bhavana, Oaknin Ana, Tinker Anna V, Sánchez Ana Beatriz, McCormick Colleen, Baurain Jean-François, O'Cearbhaill Roisin E, Denys Hannelore, Hietanen Sakari, Moore Richard G, Knudsen Anja Ør, González-Martín Antonio, de La Motte Rouge Thibault, Heitz Florian, Levy Tally, York Whitney, Gupta Divya, Monk Bradley J, Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
• Gynecologic oncology
  Randall Leslie M., O'Malley David M., Gaillard Stephanie, Holloway Robert W., Huang Marilyn, Dalton Heather, Monk Bradley J., Coleman Robert L., Adams Sarah, Duska Linda R., , Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
  178, p. 161 - 169 2023
• Journal of clinical oncology
  Gourley Charlie, Buscema Joseph, Dalton Heather J., Banerjee Susana N., Lockley Michelle, Krell Jonathan, Monk Bradley J., PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer
  36:15_suppl, p. TPS5612 - TPS5612 2018